zurück

Brivaracetam (new indication: partial onset seizures in patients with epilepsy, adjunctive therapy, patients aged 2 –

Subject:

  • Active Substance: Brivaracetam
  • Name: Briviact®
  • Therapeutic area: Epilepsy
  • Pharmaceutical company: UCB Pharma GmbH

Time table:

  • Start: 01.03.2022
  • Final decision by G-BA: 01.09.2022

Final decision:

  • No additional benefit proved